Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MRK Merck & Co Inc
- Stocks
- Healthcare
- NYSE: MRK
Price (delayed)
$80.43
Market cap
$201.96B
P/E Ratio
11.67
Dividend/share
$3.16
EPS
$6.89
Enterprise value
$228.18B
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the
Highlights
The P/E is 83% lower than the 5-year quarterly average of 70.1 and 37% lower than the last 4 quarters average of 18.6
Merck's equity has increased by 20% YoY and by 4.4% from the previous quarter
MRK's quick ratio is up by 18% year-on-year but it is down by 4.8% since the previous quarter
Key stats
What are the main financial stats of MRK
Market
Valuations
Earnings
Shares outstanding
2.51B
Market cap
$201.96B
Enterprise value
$228.18B
Price to earnings (P/E)
11.67
Price to book (P/B)
4.2
Price to sales (P/S)
3.17
EV/EBIT
10.65
EV/EBITDA
8.76
EV/Sales
3.57
Revenue
$63.92B
Gross profit
$48.85B
Operating income
$20.14B
Net income
$17.43B
EBIT
$21.43B
EBITDA
$26.05B
Free cash flow
$17.04B
Per share
Balance sheet
Liquidity
EPS
$6.89
EPS diluted
$6.87
Free cash flow per share
$6.75
Book value per share
$19.13
Revenue per share
$25.34
TBVPS
$30.79
Total assets
$115.12B
Total liabilities
$66.72B
Debt
$34.84B
Equity
$48.34B
Working capital
$10.33B
Debt to equity
0.72
Current ratio
1.41
Quick ratio
0.8
Net debt/EBITDA
1.01
Margins
Efficiency
Dividend
EBITDA margin
40.7%
Gross margin
76.4%
Net margin
27.3%
Operating margin
31.5%
Return on assets
15.1%
Return on equity
38.2%
Return on invested capital
28.5%
Return on capital employed
23.8%
Return on sales
33.5%
Dividend yield
3.93%
DPS
$3.16
Payout ratio
45.9%
MRK stock price
How has the Merck stock price performed over time
Intraday
5.87%
1 week
-2.91%
1 month
1.58%
1 year
-38.16%
YTD
-19.15%
QTD
-10.39%
Financial performance
How have Merck's revenue and profit performed over time
Revenue
$63.92B
Gross profit
$48.85B
Operating income
$20.14B
Net income
$17.43B
Gross margin
76.4%
Net margin
27.3%
The gross profit has grown by 7% year-on-year
The revenue has grown by 4.1% YoY
MRK's gross margin is up by 2.7% year-on-year
MRK's net margin is up by 2.2% since the previous quarter
Price vs fundamentals
How does MRK's price correlate with its fundamentals
Growth
What is Merck's growth rate over time
Valuation
What is Merck stock price valuation
P/E
11.67
P/B
4.2
P/S
3.17
EV/EBIT
10.65
EV/EBITDA
8.76
EV/Sales
3.57
The P/E is 83% lower than the 5-year quarterly average of 70.1 and 37% lower than the last 4 quarters average of 18.6
The price to book (P/B) is 33% lower than the 5-year quarterly average of 6.3 and 29% lower than the last 4 quarters average of 5.9
Merck's equity has increased by 20% YoY and by 4.4% from the previous quarter
MRK's P/S is 30% below its 5-year quarterly average of 4.5 and 26% below its last 4 quarters average of 4.3
The revenue has grown by 4.1% YoY
Efficiency
How efficient is Merck business performance
Merck's ROE has decreased by 2.6% from the previous quarter
Dividends
What is MRK's dividend history
DPS
$3.16
Dividend yield
3.93%
Payout ratio
45.9%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Merck financials performed over time
The total assets is 73% more than the total liabilities
MRK's quick ratio is up by 18% year-on-year but it is down by 4.8% since the previous quarter
The current ratio has grown by 13% YoY and by 3.7% from the previous quarter
MRK's debt is 28% smaller than its equity
Merck's equity has increased by 20% YoY and by 4.4% from the previous quarter
The debt to equity has contracted by 15% YoY and by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.